{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1151.52","meta":{"source":"https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1151.52/expansion"},"url":"http://vsac.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.52","version":"CMS Pre-rulemaking eCQM 2020-05-07","name":"BCGBacillusCalmetteGuerinForUrologyCare","title":"BCG Bacillus Calmette Guerin for Urology Care","status":"active","date":"2020-02-07","description":"(Clinical Focus: BCG is used for the treatment of non muscle invasive bladder cancer and is administered intravesically.),(Data Element Scope: The intent of this data element is to include prescribable BCG as a treatment for non muscle invasive bladder cancer.),(Inclusion Criteria: Bacillus Calmette Guerin for intravesical use),(Exclusion Criteria: None)","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"2020-01","concept":[{"code":"1653484","display":"BCG, Live, Tice Strain 50 MG/ML Topical Suspension"},{"code":"1653579","display":"BCG, Live, Tice Strain 50 MG Injection"}]}]}}